COMP <GO>
DNTH vs TVTX // ENTERPRISE SCALE & MARKET CAP
Dianthus Therapeutics Inc. (NASDAQ) VS. Travere Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: DNTH 2
— TVTX 8
▲ ENTERPRISE SCALE & MARKET CAP LEADER: TVTX
LAST: $82.25 (-0.16%) • MKT CAP: $4.61B
market-cap
$4.61B
LAST: $49.26 (-2.24%) • MKT CAP: $4.75B
market-cap
$4.75B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DNTH VS. TVTX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | DNTH | TVTX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 96.00% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -30.70% | -13.00% | -17.70 | TVTX | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.79% | 0.33% | -3.12 | TVTX | /fcf-yield <GO> |
| Operating Margin | -60.00% | -12.80% | -47.20 | TVTX | /operating-margins <GO> |
| Net Profit Margin | -60.00% | -5.20% | -54.80 | TVTX | /net-margins <GO> |
| Revenue Growth (YoY) | -65.00% | 110.50% | -175.50 | TVTX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 3.44 | +22.56 | DNTH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | TVTX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.8 | 35.8 | +11.00 | DNTH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 1.08 | 0.00 | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 20.0x | 18.0x | +2.00 | TVTX | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $4.61B | $4.75B | -$141.9M | TVTX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | DNTH REV | TVTX REV | DNTH GROSS % | TVTX GROSS % | DNTH FCF | TVTX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.0M | $490.7M | — | 97.9% | -$129.2M | $15.7M |
| FY 2024 | $6.2M | $233.2M | — | 96.7% | -$78.5M | -$248.0M |
| FY 2023 | $2.8M | $145.2M | — | — | -$37.0M | -$286.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DNTH // BETA 1.08
TVTX // BETA 1.08